相关实验视频
Updated: Jun 16, 2025

11:51
Facile Preparation of 4-Substituted Quinazoline Derivatives
Published on: February 15, 2016
11.9K
1,4-纳夫托金的8-基林衍生物:合成,计算分析和抗癌活性
Arkadiusz Sokal1,2, Roman Wrzalik3, Małgorzata Latocha4
1Department of Organic Chemistry, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia, 4 Jagiellońska Str., 41-200 Sosnowiec, Poland.
International journal of molecular sciences
|June 13, 2025
概括
结合1,4-纳夫托金和8-基因基架的新型异环抗癌药物候选药物显示出有前途的口服生物可用性和反应性. 这些新型杂交体显示出治疗与NQO1蛋白过度表达相关的癌症的潜力.
科学领域:
- 药用化学 医学化学
- 药物发现 药物发现 药物发现
- 异环化学 异环化学
背景情况:
- 异环混合体正在彻底改变抗癌药物设计.
- 结合素支架会影响化合物的活性,毒性和生物可用性.
- 1,4-纳夫托金衍生物正在研究它们的治疗潜力.
研究的目的:
- 合成1,4-纳夫托基与8-基基诺林部分的新杂交物.
- 评估这些新化合物的生物活性和物理化学特性.
- 评估它们作为抗癌剂的潜力,特别是针对NQO1-过度表达的癌细胞.
主要方法:
- 光谱表征 (HR-MS,NMR,IR) 和计算光谱分析.
- 物理化学性质和生物可用性的in silico评估.
- 在体外评估NQO1蛋白的酶转化和对癌症细胞系的抗增殖活性.
- 分子对接以调查连接体-蛋白相互作用.
主要成果:
- 合成和表征了新的1,4-纳夫托基诺-8-基诺林杂交物.
- 在分析表明了良好的电子受体特性,高反应性和良好的口服生物可用性.
- 化合物显示了NQO1酶转化潜力和对相关癌症细胞系的抗增殖作用.
- 分子对接表明可能与NQO1蛋白的相互作用.
结论:
- 合成的混合物代表了抗癌药物开发的有希望的候选人.
- 它们有利的in silico特性表明它们适合于口服.
- 需要进一步研究它们与NQO1蛋白的相互作用以及体内疗效.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
154
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
154
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K

